Memory decline shows stronger associations with estimated spatial patterns of amyloid deposition progression than total amyloid burden.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Neurobiology of Aging

• Publication date

  2013-12-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.neurobiolaging.2013.05.030PMID 23859610PMCID PMC3893024
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease.

  2012cited by this paper
• Longitudinal imaging pattern analysis (SPARE-CD index) detects early structural and functional changes before cognitive decline in healthy older adults.

  2012cited by this paper
• MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults

  2012cited by this paper
• Longitudinal patterns of β-amyloid deposition in nondemented older adults.

  2011cited by this paper
• Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease

  2011cited by this paper
• Face-name associative memory performance is related to amyloid burden in normal elderly.

  2011cited by this paper
• In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults.

  2011cited by this paper
• Amyloid imaging and memory change for prediction of cognitive impairment

  2011cited by this paper
• Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.

  2011influential reference
• In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18)

  2010cited by this paper
• Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ) deposition

  2010cited by this paper
• Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB

  2010cited by this paper
• The use of PET in Alzheimer disease

  2010cited by this paper
• Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

  2010cited by this paper
• Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease

  2009influential reference
• Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects.

  2009cited by this paper
• Clinical severity of Alzheimer's disease is associated with PIB uptake in PET.

  2009cited by this paper
• The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal

  2009cited by this paper
• High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters.

  2009cited by this paper
• Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition.

  2009cited by this paper
• Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.

  2008cited by this paper
• Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease

  2008cited by this paper
• Longitudinal Cerebral Blood Flow and Amyloid Deposition: An Emerging Pattern?

  2008cited by this paper
• Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease.

  2008cited by this paper
• PET imaging of amyloid deposition in patients with mild cognitive impairment.

  2008cited by this paper
• 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.

  2008cited by this paper
• Imaging beta-amyloid burden in aging and dementia.

  2007cited by this paper
• PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis.

  2007cited by this paper
• Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease

  2007cited by this paper
• β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease

  2007influential reference
• Imaging β-amyloid burden in aging and dementia

  2007cited by this paper
• Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease.

  2007cited by this paper
• Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

  2006cited by this paper
• [11C]PIB in a nondemented population

  2006cited by this paper
• Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.

  2005cited by this paper
• Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B

  2005cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

  2004influential reference
• Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model

  2003cited by this paper
• Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.

  2002cited by this paper
• Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer Type

  1997influential reference
• Frequency of stages of Alzheimer-related lesions in different age categories.

  1997cited by this paper
• Staging of Alzheimer-related cortical destruction.

  1997influential reference
• Frequency of stages of Alzheimer-related lesions in different age categories.

  1997influential reference
• Controlling the false discovery rate: a practical and powerful approach to multiple testing

  1995cited by this paper
• Correction of PET Data for Partial Volume Effects in Human Cerebral Cortex by MR Imaging

  1990cited by this paper
• The Association Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects

  1968cited by this paper

• Rates of β-amyloid deposition indicate widespread simultaneous accumulation throughout the brain.

  2022cites this paper
• Beam orientation optimization for coherent X-ray scattering from distributed deep targets

  2021cites this paper
• Vascular Cognitive Impairment

  2021cites this paper
• Imaging in Cerebral Small Vessel Disease

  2019cites this paper
• Cerebral Small-Vessel Disease

  2019cites this paper
• Spatial pattern of beta-amyloid accumulation in Alzheimer’s disease as measured with positron emission tomography

  2018influential citation
• The Additional Value of PET in the Assessment of Cerebral Small Vessel Disease

  2018cites this paper
• Stereological Quantification of Plaques and Tangles in Neocortex from Alzheimer’s Disease Patients

  2018cites this paper
• Neuroimaging in Cerebral Small Vessel Disease

  2018cites this paper
• Imaging Morphologic Substrates and Molecular Changes for Differential Diagnosis of Vascular Dementia

  2017cites this paper
• Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility

  2017cites this paper
• Predicting Regional Pattern of Longitudinal β-Amyloid Accumulation by Baseline PET

  2017influential citation
• Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project

  2017cites this paper
• Could ecosystem management provide a new framework for Alzheimer's disease?

  2016cites this paper
• Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective

  2016cites this paper
• Computerized Cognitive Tests Are Associated with Biomarkers of Alzheimer’s Disease in Cognitively Normal Individuals 10 Years Prior

  2016cites this paper
• Neurologische und dementielle Erkrankungen

  2016cites this paper
• Microvascular and blood-brain barrier dysfunction in Alzheimer’s disease

  2016cites this paper
• Neuroimaging in vascular cognitive impairment: a state-of-the-art review

  2016cites this paper
• Alzheimer Mythology: A Time to Think Out of the Box.

  2016cites this paper
• Temporal Order of Alzheimer’s Disease-Related Cognitive Marker Changes in BLSA and WRAP Longitudinal Studies

  2016cites this paper
• Alzheimer’s Disease Dementia, Amyloid Imaging and Underpinning Fibrillar A? Plaque Associated Pathology: Are They Aligned?

  2015cites this paper
• The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data

  2015cites this paper
• Voxelwise Relationships Between Distribution Volume Ratio and Cerebral Blood Flow: Implications for Analysis of β-Amyloid Images

  2015cites this paper
• The Role of PICALM in Alzheimer’s Disease

  2014cites this paper
• MR-Less Surface-Based Amyloid Assessment Based on 11C PiB PET

  2014cites this paper
• Cerebral and blood correlates of reduced functional connectivity in mild cognitive impairment

  2014cites this paper
• Gadolinium-based contrast agents targeted to amyloid aggregates for the early diagnosis of Alzheimer's disease by MRI.

  2014cites this paper
• Animal models of Alzheimer disease: historical pitfalls and a path forward.

  2014cites this paper
• Oral delivery of bioencapsulated proteins across blood-brain and blood-retinal barriers.

  2014cites this paper